Table 1 Characteristics of the included studies in meta-analysis
studies | Country | Study Design | Participant | Sample size and Sex | Sample size | Intervention Duration (Week) | Means Age | Means BMI | Intervention | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IG | CG | IG | CG | IG | CG | Paricalcitol dose (µg/d) | Control group | ||||||
Alborzi et al. 2008(a) | USA | Parallel, R, PC, DB | patients with Chronic Kidney Disease | 16 F:14 M:2 | 8 | 8 | 4 | 72.6 ± 9.1 | 68.4 ± 12.4 | 34.3 ± 9.1 | 35.4 ± 7.7 | 1 | Placebo |
Alborzi et al. 2008(b) | USA | Parallel, R, PC, DB | patients with Chronic Kidney Disease | 16 F:14 M:2 | 8 | 8 | 4 | 67.5 ± 9.1 | 68.4 ± 12.4 | 35.0 ± 6.5 | 35.4 ± 7.7 | 2 | Placebo |
Lundwall et al. 2015(a) | Sweden | paralell, R, PC, DB | patients with Non-Diabetic Chronic Kidney Disease | 24 F:4 M:20 | 12 | 12 | 12 | 66.1 ± 7.9 | 59.1 ± 11.6 | 26.4 ± 3.5 | 26.8 ± 2.8 | 1 | Placebo |
Lundwall et al. 2015(b) | Sweden | paralell, R, PC, DB | patients with Non-Diabetic Chronic Kidney Disease | 24 F:NR M:NR | 12 | 12 | 12 | 70.8 ± 10.0 | 59.1 ± 11.6 | 28.1 ± 2.4 | 26.8 ± 2.8 | 2 | Placebo |
Thethi et al. 2015 | USA | paralell, R, PC, DB | patients with type 2 diabetes and chronic kidney disease | 46 F:NR M:NR | 23 | 23 | 12 | 64 ± 4.5 | 61 ± 5 | NR | NR | 1 | Placebo |
Zoccali et al. 2014 | Italy | paralell, R, PC, DB | patients with Chronic Kidney Disease | 88 F:31 M:57 | 44 | 44 | 12 | 63 ± 11 | 62 ± 12 | 29 ± 5 | 29 ± 5 | 2 | Placebo |